DXCM vs SYK: fair value comparison
DexCom, Inc. and Stryker Corporation · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, SYK currently sits closer to the top of our ranking by discount to fair value.
| DXCM | SYK | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $84.11 | $277.33 |
| 12-month range | $54.84–$92.34 | $269.75–$387.46 |
| Rank by discount to fair value | #13 of 108 Healthcare | #12 of 108 Healthcare |
| Quality grade | A | A |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: DXCM fair value analysis · SYK fair value analysis